# Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids

> **NCT01388764** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 7 (actual)

## Conditions studied

- Dystrophinopathy
- Duchenne Muscular Dystrophy
- Becker's Muscular Dystrophy

## Interventions

- **DRUG:** L-arginine

## Key facts

- **NCT ID:** NCT01388764
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2012-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01388764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01388764, "Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01388764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*